Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 -- -- Received FDA clearance of Investigational New Drug application for PM647 in Alpha-1 Antitrypsin Deficiency; initial clinical data expected in 2027 -- -- Planning for a BLA submission for PM359 in the first half of 2027 -- -- Closed underwritten public offering, including the full exercise of the underwriters’ option to purchase additional shares, raising $143.7 million in gross proceeds -- -- Pro-forma cash, cash equivalents, investments and restricted cash of a